Stockscreener 앱 받기
4.99
1.96%
-0.10
전일 마감가:
$5.09
열려 있는:
$5.02
하루 거래량:
2.57M
Relative Volume:
2.45
시가총액:
$320.64M
수익:
-
순이익/손실:
$-27.03M
주가수익비율:
-5.9405
EPS:
-0.84
순현금흐름:
$-23.97M
1주 성능:
-32.38%
1개월 성능:
-39.44%
6개월 성능:
+161.26%
1년 성능:
+219.87%
1일 변동 폭
$4.73
$5.34
1주일 범위
$3.7701
$7.44
52주 변동 폭
$1.30
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
863 MITTEN ROAD, BURLINGAME, CA
CRVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.99 | 320.64M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Interim Data from Atopic Dermatitis TrialBURLINGAME, Calif. – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) disclosed key interim data from its randomized, double-blind, placebo-controlled Phase 1 cl - Defense World
Corvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade) - Seeking Alpha
Corvus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRVS) - Defense World
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - AOL
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS) - Seeking Alpha
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Stock Traders Buy High Volume of Put Options on Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Corvus stock falls after eczema trial data (CRVS:NASDAQ) - Seeking Alpha
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost - TipRanks
Corvus Pharmaceuticals Shares Surge 7% After Positive Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis - mediahousepress
Corvus Pharmaceuticals stock falls despite promising early trial results - Investing.com
Corvus Pharmaceuticals Announces Interim Data from - GlobeNewswire
Form 8-K Corvus Pharmaceuticals, For: Dec 18 - StreetInsider.com
Corvus Pharma's Atopic Dermatitis Drug Shows Promising 69% Efficacy in Phase 1 Trial Data - StockTitan
Why US Futures Are Rising WednesdayCorvus Pharma (NASDAQ:CRVS), Applied DNA Sciences (NASDAQ:APDN) - Benzinga
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus to share soquelitinib trial data for skin condition By Investing.com - Investing.com Australia
Corvus to share soquelitinib trial data for skin condition - Investing.com India
Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding - MarketWatch
Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal - MarketWatch
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - The Manila Times
Corvus Pharma Set to Unveil Key Atopic Dermatitis Trial Data for Soquelitinib in December - StockTitan
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Increase in Short Interest - MarketBeat
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% - Yahoo Finance
Trading (CRVS) With Integrated Risk Controls - Stock Traders Daily
Point72 Asset Management L.P. Decreases Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Individual investors are Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) biggest owners and were hit after market cap dropped US$89m - Simply Wall St
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity - The Manila Times
CRVSCorvus Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Corvus Pharma's Cancer Drug Shows Breakthrough Immune Response in Nature Journal Study - StockTitan
Connor Clark & Lunn Investment Management Ltd. Grows Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FY2024 EPS Estimates for CRVS Cut by Cantor Fitzgerald - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC - MarketBeat
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - The Manila Times
Corvus drug shows promise in systemic sclerosis models - Investing.com
Corvus' Soquelitinib Shows Promise in Preventing Systemic Sclerosis Lung Damage in Key Study | CRVS Stock News - StockTitan
Corvus Pharmaceuticals target raised to $13 by Jefferies - Investing.com UK
Corvus Pharmaceuticals: The Market Likes The Story (NASDAQ:CRVS) - Seeking Alpha
Earnings call: Corvus Pharmaceuticals reports Q3 financials and trial updates - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst Upgrade - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Corvus: Q3 Earnings Snapshot - San Antonio Express-News
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Corvus Pharma Reports $41.7M Cash Position, Advances Key Clinical Trials Despite Q3 Loss | CRVS Stock News - StockTitan
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):